Covalon Technologies (COV) Q3 2025 earnings summary

Executive summary

• Achieved sequential quarter-on-quarter revenue growth of 10.4% and adjusted EBITDA growth of over 50% in Q3 FY2025, fulfilling prior guidance and demonstrating strong operational execution.

• Trailing twelve months revenue grew 13%, with adjusted EBITDA up 116% and cash on hand exceeding $18 million.

• Advanced clinical evidence and market development, including peer-reviewed studies and new product indications, supporting future growth.

• Expanded international presence with product registrations in Canada, Brazil, Panama, new distribution agreements, and tender wins in Israel and India.

• U.S. shares are now DTC eligible, improving accessibility for American investors.

Financial highlights

• Q3 FY2025 revenue was $8.4 million, up over 10% sequentially but down 9% year-over-year due to inventory normalization and timing of purchase orders.

• Adjusted gross margin for Q3 was 56% after excluding over $800,000 in one-time inventory-related charges; reported gross margin was 46.5%.

• Adjusted EBITDA for Q3 was just under $0.9 million, more than 50% higher than Q2, but $1.5 million lower year-over-year.

• Year-to-date revenue grew 8% to $24.1 million and adjusted EBITDA reached $3 million, slightly down from last year.

• Cash on hand stands at over $18 million, up nearly $9 million year-over-year, with positive cash generation for five consecutive quarters and no debt.

Outlook and guidance

• Management expects continued sequential revenue growth in Q4 and remains bullish on strong growth into next year, with a clear multi-year growth opportunity.

• Margins are expected to stabilize following one-time Q3 events, supporting improved EBITDA in Q4 and beyond.

• New clinical evidence and expanded product indications are anticipated to accelerate product adoption and open new revenue streams.